CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer

The successful use of immune cell checkpoint inhibitors PD-1 and PD-L1, over the past 5 y has raised the concern of using immunotherapy to treat various cancers. Epstein-Barr virus-associated gastric cancer (EBVaGC) exhibits high infiltration of lymphocytes and high amplification of immune-related g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Su, Shu, Zou, Zhengyun, Chen, Fangjun, Ding, Naiqing, Du, Juan, Shao, Jie, Li, Lin, Fu, Yao, Hu, Bian, Yang, Yang, Sha, Huizi, Meng, Fanyan, Wei, Jia, Huang, Xingxu, Liu, Baorui
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5283615/
https://ncbi.nlm.nih.gov/pubmed/28197365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1249558
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars